Latest news
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeatMarketBeat · Sun, 09 Aug 2026 06:21:56 GMTIKT|Inhibikase Therapeutics Inc|Price:2.430|Chg%:+0.220 - TradingKeyTradingKey · Mon, 03 Aug 2026 07:00:00 GMTPerceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT - MarketBeatMarketBeat · Sun, 02 Aug 2026 07:00:00 GMTInhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT - TradingViewTradingView · Sat, 01 Aug 2026 02:14:09 GMT18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT) - Stock TitanStock Titan · Fri, 31 Jul 2026 20:33:04 GMTRA Capital group (NASDAQ: IKT) discloses 9.99% capped stake via stock and warrants - Stock TitanStock Titan · Fri, 31 Jul 2026 07:00:00 GMTH.C. Wainwright Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8 - MoomooMoomoo · Fri, 31 Jul 2026 07:00:00 GMTInhibikase Therapeutics Inc (IKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKeyTradingKey · Fri, 31 Jul 2026 07:00:00 GMT